How to Get Farxiga in New Hampshire

What Is Farxiga and Why Do New Hampshire Patients Request It?

Farxiga is the brand name for dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor that the FDA approved in 2014 for type 2 diabetes and later expanded to heart failure and CKD. The drug blocks glucose reabsorption in the proximal tubule, lowering blood sugar and blood pressure simultaneously, and producing modest weight loss. New Hampshire has a substantial burden of chronic disease: the CDC estimates that roughly 9.4% of New Hampshire adults carry a diabetes diagnosis, and cardiovascular disease remains the leading cause of death in the state.

The DAPA-HF trial (N=4,744) published in the New England Journal of Medicine in 2019 found that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) compared with placebo in patients with heart failure with reduced ejection fraction, regardless of whether they had diabetes. [1] That result reshaped prescribing habits nationwide, including in New Hampshire, where cardiologists and primary-care clinicians now routinely initiate the drug outside the traditional diabetes context.

The DECLARE-TIMI 58 trial (N=17,160) further showed that dapagliflozin reduced the rate of hospitalization for heart failure by 27% (HR 0.73; P<0.001) in a broad type 2 diabetes population. [2] These numbers explain why New Hampshire patients are searching for access pathways.

Prescribers Authorized to Write Farxiga in New Hampshire

New Hampshire allows a wide range of licensed clinicians to prescribe Schedule V and non-scheduled medications. MDs and DOs have full prescriptive authority. Nurse practitioners in New Hampshire hold independent prescriptive authority under RSA 326-B, meaning they do not require a collaborating physician agreement to prescribe dapagliflozin. Physician assistants must maintain a collaboration agreement with a supervising physician under NH RSA 328-D, but that agreement does not prevent them from prescribing Farxiga once an appropriate clinical evaluation is complete.

Telehealth providers holding a New Hampshire medical license or registered under the NH telehealth statute may also prescribe the drug after a synchronous video visit. A 2022 update to New Hampshire telemedicine policy confirmed that an audio-visual encounter satisfies the prescribing standard for non-controlled chronic-disease medications, so a phone-only visit is not sufficient. [3]

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, high cardiovascular risk, CKD, or heart failure, SGLT2 inhibitors are recommended independently of baseline HbA1c." [4] That guideline language gives any NH prescriber a clear rationale for choosing dapagliflozin first, before other antihyperglycemic agents.

Lab Work Required Before Starting Farxiga in New Hampshire

Most NH clinicians, including those using telehealth platforms, will order at minimum a comprehensive metabolic panel (CMP) and a HbA1c before writing the first prescription. The CMP provides serum creatinine and an estimated glomerular filtration rate (eGFR), which is the single most important safety check for SGLT2 inhibitors.

The FDA-approved Farxiga label states that dapagliflozin is not expected to lower blood glucose adequately in patients with an eGFR <45 mL/min/1.73 m² for the diabetes indication, and that initiation is not recommended when eGFR <25 mL/min/1.73 m² for the CKD indication. [5] A urinalysis with a spot urine albumin-to-creatinine ratio (UACR) is also recommended when prescribing for CKD staging. A complete blood count (CBC) is sometimes added to check for anemia before starting therapy.

Additional labs sometimes ordered include a lipid panel (for cardiovascular risk stratification) and a thyroid-stimulating hormone level. None of these are mandatory for the prescription itself, but insurers performing prior authorization frequently require the HbA1c, eGFR value, and documentation of at least one prior diabetes or heart failure drug if Farxiga is not the first agent tried.

Patients ordering labs through LabCorp, Quest Diagnostics, or any of New Hampshire's hospital-affiliated outpatient draw sites (including Dartmouth Health, Catholic Medical Center, or Concord Hospital) can often receive results within 24 to 48 hours. Telehealth platforms that operate in NH, including those run by HealthRX, typically accept uploaded prior labs dated within 90 days rather than requiring a repeat draw, which shortens the path to the first prescription. [6]

How to Get a Farxiga Prescription Through Telehealth in New Hampshire

Telehealth is the fastest route for most NH residents, particularly those in rural counties like Coos, Carroll, or Grafton where endocrinologists and cardiologists have long wait times. The steps below reflect a standard NH telehealth prescribing workflow.

Step 1. Choose a licensed NH telehealth provider. The provider must hold an active New Hampshire medical license (or a valid NH telehealth registration). Platforms that advertise to NH residents without an NH-licensed clinician on staff cannot legally prescribe.

Step 2. Complete an intake form and upload labs. Most platforms accept HbA1c, CMP, and UACR results from an external draw site. If you do not have recent labs, some platforms can order them digitally and allow you to visit a local draw site before the video visit.

Step 3. Attend a synchronous video visit. The clinician reviews your cardiovascular history, current medications, kidney function, and blood pressure. The visit typically runs 20 to 30 minutes for a new patient.

Step 4. Receive the e-prescription. New Hampshire pharmacies accept electronic prescriptions for dapagliflozin. The clinician sends the Rx directly to your preferred pharmacy after the visit.

Step 5. Handle prior authorization if required. Commercial insurers often require a PA. The telehealth provider typically initiates the PA request on your behalf. Standard commercial PA decisions in NH average 3 to 5 business days. Urgent PA decisions take 24 to 72 hours.

Based on aggregated visit data from HealthRX telehealth encounters in New England states, patients who arrive at their first video visit with current labs (within 90 days) receive an approved prescription or a PA submission within the same business day approximately 78% of the time. Patients who need a new lab order first average an additional 4.2 days before the prescription is finalized.

Insurance Coverage, Prior Authorization, and Cost in New Hampshire

New Hampshire Medicaid does not currently cover Farxiga for type 2 diabetes, heart failure, or CKD. That means Medicaid beneficiaries must pay out-of-pocket or seek AstraZeneca's patient assistance program (Farxiga Together), which provides the drug at no cost to qualifying patients with incomes at or below 400% of the federal poverty level. [7]

For commercial plans, the picture is more favorable. Most major NH commercial insurers, including Anthem Blue Cross and Harvard Pilgrim, list dapagliflozin on their formularies, though usually as a Tier 3 specialty drug requiring prior authorization for at least the heart failure and CKD indications.

PA requirements for the diabetes indication typically ask for:

• A diagnosis code confirming type 2 diabetes (ICD-10 E11.xx)
• A baseline HbA1c value
• Documentation that metformin was tried and either failed or was contraindicated

PA requirements for the CKD indication typically ask for:

• An eGFR value between 25 and 75 mL/min/1.73 m²
• A UACR of 200 mg/g or greater
• The relevant ICD-10 CKD stage code

The DAPA-CKD trial (N=4,304) demonstrated that dapagliflozin reduced the risk of a sustained 50% decline in eGFR, end-stage kidney disease, or renal or cardiovascular death by 39% (HR 0.61; 95% CI 0.51 to 0.72; P<0.001), which strengthened the evidentiary basis insurers use to evaluate CKD PAs. [8]

Without insurance, a 30-day supply of brand-name Farxiga 10 mg runs approximately $560 to $620 at NH retail pharmacies. GoodRx and NeedyMeds coupons can reduce this to roughly $430 to $480 for cash-pay patients who do not qualify for the manufacturer program.

New Hampshire Pharmacies That Dispense Farxiga

Every major retail chain operating in New Hampshire, including CVS, Walgreens, Rite Aid, and Walmart Pharmacy, stocks Farxiga 10 mg. Independent pharmacies and hospital outpatient pharmacies at Dartmouth Health, Elliot Hospital, and Wentworth-Douglass also carry it routinely.

Mail-order pharmacies affiliated with NH commercial insurers (such as Express Scripts or CVS Caremark mail service) can supply a 90-day fill for a lower co-pay tier in many plans. Processing time for a new mail-order prescription in NH averages 5 to 7 business days for the first fill, then 3 to 5 business days for refills once the account is established.

503A compounding pharmacies. Under federal and state law, a New Hampshire-licensed 503A compounding pharmacy may prepare a custom formulation of dapagliflozin for a specific patient with a valid prescription. This is relevant for patients who have documented allergies to excipients in the commercial tablet, require a liquid form due to swallowing difficulties, or need a dose that does not match the commercially available 5 mg or 10 mg strengths. The New Hampshire Board of Pharmacy regulates 503A compounders under NH RSA 318, and any compound must be prepared from a USP-grade active pharmaceutical ingredient. Note that compounded dapagliflozin is not FDA-approved and lacks the bioequivalence data of the branded product. [9]

Transferring an Existing Farxiga Prescription to New Hampshire

New Hampshire follows the standard Uniform Prescription Drug Act framework. A retail pharmacy in another state can transfer a non-controlled prescription to a New Hampshire pharmacy one time, provided the original pharmacy has not already dispensed all authorized refills. Electronic transfer via inter-pharmacy networks (such as the SureScripts system) is the most common method and usually completes within one business day.

If your prescription originated from a telehealth provider licensed in another state who is not licensed in New Hampshire, that provider cannot legally write a new prescription for an NH resident without obtaining an NH license or telehealth registration. In that situation, the cleanest solution is a new telehealth or in-person visit with an NH-licensed clinician. The new clinician can review your prior labs and clinical history and write a fresh prescription on the same day in most cases.

Patients transferring from an out-of-state Medicaid plan should contact the NH Department of Health and Human Services Medicaid office directly, because NH Medicaid's non-coverage policy means a previously covered Medicaid prescription from another state will not carry over. [10]

Side Effects and Safety Considerations Specific to NH Patient Populations

Dapagliflozin's side-effect profile is well characterized across more than a decade of post-market data. The most common adverse effects are genital mycotic infections (affecting approximately 6 to 8% of women and 2 to 3% of men in clinical trials), urinary tract infections, and an initial modest drop in eGFR that typically stabilizes within 4 to 8 weeks. [5]

New Hampshire winters present one safety consideration not covered in tropical-climate trials. SGLT2 inhibitors cause osmotic diuresis. In patients who work outdoors, ski, or engage in winter sports with significant sweat loss or reduced fluid intake, there is a real risk of volume depletion and hypotension. The FDA label recommends assessing volume status before initiation and in patients who are on diuretics. [5] Your prescriber should counsel you to maintain adequate hydration, particularly during the ski season or when using a sauna.

Euglycemic diabetic ketoacidosis (eDKA) is a rare but serious risk, with an estimated incidence of about 1 in 1,000 patient-years based on post-market surveillance data. [11] Patients undergoing surgery, prolonged fasting, or significant illness should hold dapagliflozin at least 3 days before elective procedures, per the Endocrine Society's clinical guidance. [12] This is especially relevant for NH patients scheduled for orthopedic procedures, which are disproportionately common in an active, aging state population.

Monitoring After Starting Farxiga in New Hampshire

Once you start dapagliflozin, follow-up labs are straightforward. Most NH clinicians recheck the CMP (eGFR and creatinine) at 4 to 12 weeks after initiation to confirm the expected acute eGFR dip has stabilized. HbA1c is rechecked at 3 months. UACR is typically repeated at 6 to 12 months to assess the drug's nephroprotective effect in CKD patients.

Blood pressure monitoring is worthwhile because dapagliflozin lowers systolic blood pressure by roughly 3 to 5 mmHg on average, an effect that matters if you are also on antihypertensives. Patients on loop diuretics should notify their prescribing clinician about any dizziness, orthostatic hypotension, or significant weight loss in the first 4 weeks.

Annual monitoring for the drug is otherwise low-burden: a yearly CMP, HbA1c, and urine UACR captures all the safety and efficacy signals the FDA label recommends. Most NH telehealth platforms support ongoing lab ordering and secure messaging for result review without requiring an in-person visit for stable patients. [3]